Loading...
Loading...
VSTM| Name | Value |
|---|---|
| Revenues | 10.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 10.0M |
| Operating Expense | 28.3M |
| Operating I/L | -18.3M |
| Other Income/Expense | 10.0M |
| Interest Income | 1.0M |
| Pretax | -8.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -8.3M |
Verastem, Inc. is a biopharmaceutical company specializing in the development and commercialization of cancer treatment drugs. Their lead product in development, VS-6766, targets rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) pathways. The company is also working on combination therapies, such as VS-6766 with defactinib for ovarian and lung cancer. Verastem has license agreements with Chugai Pharmaceutical Co., Ltd. and Pfizer Inc. for product development and commercialization. Additionally, they have a clinical collaboration agreement with Amgen, Inc. to evaluate combination therapies. These partnerships and drug development activities are key to Verastem's revenue generation.
